Evaluation of Promotility Agents to Limit the Gut Bioavailability of Extended-Release Acetaminophen

Journal of Toxicology - Clinical Toxicology

Volumn 42, Issue 1, 2004, Pages 73-77

  Amato, Christopher S ^a   Wang, Richard Y ^b   Wright, Robert O ^c   Linakis, James G ^d,e  

^a MORRISTOWN MEMORIAL HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HASBRO CHILDREN'S HOSPITAL   (United States)

^e RHODE ISLAND HOSPITAL   (United States)

Author keywords

Acetaminophen; Erythromycin; Neostgmine; Promotility agents

Indexed keywords

ERYTHROMYCIN; EXTENDED RELIEF TYLENOL; NEOSTIGMINE; PARACETAMOL; PLACEBO; PROKINETIC AGENT;

ABDOMINAL CRAMP; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; HYPERSALIVATION; INTESTINE MOTILITY; MALE; MUSCLE TWITCH; NAUSEA; NORMAL HUMAN; SIDE EFFECT;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DIGESTIVE SYSTEM; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NEOSTIGMINE;

EID: 1842481384     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-120028748     Document Type: Article

References (16)

1. Perrone J, Hoffman RS, Goldfrank LR. Special considerations in gastrointestinal decontamination. Emerg Med Clin North Am 1994; 12(2):285-299.
2. Tenenbein M, Cohen S, Sitar DS. Efficacy of ipecac-induced emesis, orogastric lavage, and activated charcoal for acute drug overdose. Ann Emerg Med 1987; 16(8):838-841.
3. Tenenbein M. Whole bowel irrigation and activated charcoal. Ann Emerg Med 1989; 18(6):707-708.
4. Fleisher GR, Kearney TE, Henretig F, Tenenbein M. Gastric decontamination in the poisoned patient. Pediatr Emerg Care 1991; 7(6):378-381.
5. American Academy of Clinical Toxicology and European Association of Poison Centres and Clinical Toxicologists. Position Statements: Cathartics, 2003. http://www.clintox.org/Pos_Statements/ Cathartics.html.
6. Tenenbein M. Recent advancements in pediatric toxicology. Pediatr Clin North Am 1999; 46(6):1179-1188.
7. Zara GP, Thompson HH, Pilot MA, Ritchie HD. Effects of erythromycin on gastrointestinal tract motility. J Antimicrob Chemother 1985; 16 (suppl A):175-179.
8. Zara GP, Qin XY, Pilot MA, Thomson HH, Maskell JP. Erythromycin and gastrointestinal motility. Lancet 1987; 2(8566):1036.
9. Boivin MA, Carey MC, Levy H. Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects. Pharmacotherapy 2003; 23(1):5-8.
10. Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990; 322(15):1028-1031.
11. Peeters TL, Bormans V, Vantrappen G. Comparison of motilin binding to crude homogenates of human and canine gastrointestinal smooth muscle tissue. Regul Pept 1988; 23(2):171-182.
12. Peeters TL, Depoortere I. Motilin receptor: a model for development of prokinetics. Dig Dis Sci 1994; 39(suppl 12):76S-78S.
13. Stephenson BM, Morgan AR, Salaman JR, Wheeler MH. Ogilvie's syndrome: a new approach to an old problem. Dis Colon Rectum 1995; 38(4):424-427.
14. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudoobstruction. N Engl J Med 1999; 341(3):137-141.
15. De Giorgio R, Barbara G, Stanghellini V, Tonini M, Vasina V, Cola B, Corinaldesi R, Biagi G, De Ponti F. Review article: the pharmacological treatment of acute colonic pseudo-obstruction. Aliment Pharmacol Ther 2001; 15(11):1717-1727.
16. Physicians' Desk Reference. 57th ed. Montvale, NJ: Thomson PDR, 2003.